AVITA Medical Inc. (RCEL)
Company Description
AVITA Medical Inc. operates as a commercial-stage regenerative tissue company in the United States, Australia, and the United Kingdom.
It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications, including vitiligo.
The company's patented and proprietary platform technology provides treatment solutions derived from the regenerative properties of a patient's own skin.
Its lead product is RECELL System, a device that enables healthcare professionals to produce a suspension of Spray-On Skin cells using a small sample of the patient's own skin for use in the treatment of acute thermal burns in patients eighteen years and older.
The company has a research collaboration with the University of Colorado School of Medicine to establish pre-clinical proof-of-concept for a spray-on treatment of genetically corrected cells; and a research collaboration with Houston Methodist Research Institute to explore molecular reversal of cellular aging through a novel cell suspension delivery system.
The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical Inc. in December 2020.
AVITA Medical Inc. was incorporated in 2000 and is based in Valencia, California.

Country | United States |
IPO Date | May 14, 2012 |
Industry | Medical - Devices |
Sector | Healthcare |
Employees | 260 |
CEO | James M. Corbett |
Contact Details
Address: 28159 Avenue Stanford Valencia, California United States | |
Website | https://www.avitamedical.com |
Stock Details
Ticker Symbol | RCEL |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001762303 |
CUSIP Number | 05380C102 |
ISIN Number | US05380C1027 |
Employer ID | 20-2578762 |
SIC Code | 3841 |
Key Executives
Name | Position |
---|---|
James M. Corbett | Chief Executive Officer, President & Executive Director |
David O'Toole | Chief Financial Officer |
David Melbye | Senior Vice President of Operations |
Debbie Garner | Senior Vice President of Global Marketing & Strategy |
Dr. Katie Bush Ph.D. | Senior Vice President of Scientific & Medical Affairs |
Dr. Niraj Doshi J.D., P.M.P., Ph.D. | Senior Vice President of Product Development & Program Management |
Jessica Ekeberg | Director of Investor Relations |
Nicole Linda Kelsey | Chief Legal & Compliance Officer and Corporate Secretary |
Rob Hall | Senior Vice President of Human Resources |
Ron Lagerquist | Senior Vice President of Quality Assurance & Regulatory Affairs |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 17, 2025 | 8-K | Current Report |
Mar 10, 2025 | 4 | Filing |
Feb 20, 2025 | 4 | Filing |
Feb 20, 2025 | 4 | Filing |
Feb 19, 2025 | 4 | Filing |
Feb 14, 2025 | 424B5 | Filing |
Feb 13, 2025 | 10-K | Annual Report |
Feb 13, 2025 | 8-K | Current Report |
Jan 29, 2025 | 4 | Filing |
Jan 22, 2025 | 4 | Filing |